Loading…

50-W vs 40-W During High-Power Short-Duration Ablation for Paroxysmal Atrial Fibrillation: A Multicenter Prospective Study

High-power short-duration (HPSD) radiofrequency ablation of atrial fibrillation (AF) increases first-pass pulmonary vein isolation (PVI) and freedom from atrial arrhythmias while decreasing procedural time. However, the optimal power setting in terms of safety and efficacy has not been determined. T...

Full description

Saved in:
Bibliographic Details
Published in:JACC. Clinical electrophysiology 2023-12, Vol.9 (12), p.2573-2583
Main Authors: Costea, Alexandru, Diaz, Juan Carlos, Osorio, Jose, Matos, Carlos D, Hoyos, Carolina, Goyal, Sandeep, Te, Charles, D'Souza, Benjamin, Rastogi, Mohit, Lopez-Cabanillas, Nestor, Ibanez, Laura C, Thorne, Christopher, Varley, Allyson L, Zei, Paul C, Sauer, William H, Romero, Jorge E
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 2583
container_issue 12
container_start_page 2573
container_title JACC. Clinical electrophysiology
container_volume 9
creator Costea, Alexandru
Diaz, Juan Carlos
Osorio, Jose
Matos, Carlos D
Hoyos, Carolina
Goyal, Sandeep
Te, Charles
D'Souza, Benjamin
Rastogi, Mohit
Lopez-Cabanillas, Nestor
Ibanez, Laura C
Thorne, Christopher
Varley, Allyson L
Zei, Paul C
Sauer, William H
Romero, Jorge E
description High-power short-duration (HPSD) radiofrequency ablation of atrial fibrillation (AF) increases first-pass pulmonary vein isolation (PVI) and freedom from atrial arrhythmias while decreasing procedural time. However, the optimal power setting in terms of safety and efficacy has not been determined. This study compared the procedural characteristics and clinical outcomes of 50-W vs 40-W during HPSD ablation of paroxysmal AF. Patients from the REAL-AF prospective multicenter registry (Real-World Experience of Catheter Ablation for Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation) undergoing HPSD ablation of paroxysmal AF, either using 50-W or 40-W, were included. The primary efficacy outcome was freedom from all-atrial arrhythmias. The primary safety outcome was the occurrence of any procedural complication at 12 months. Secondary outcomes included procedural characteristics, AF-related symptoms, and the occurrence of transient ischemic attack or stroke at 12 months. A total of 383 patients were included. Freedom from all-atrial arrhythmias at 12 months was 80.7% in the 50-W group and 77.3% in the 40-W group (Log-rank P = 0.387). The primary safety outcome occurred in 3.7% of patients in the 50-W group vs 2.8% in the 40-W group (P = 0.646). The 50-W group had a higher rate of first-pass PVI (82.3% vs 76.2%; P = 0.040) as well as shorter procedural (67 minutes [IQR: 54-87.5 minutes] vs 93 minutes [IQR: 80.5-111 minutes]; P < 0.001) and radiofrequency ablation times (15 minutes [IQR: 11.4-20 minutes] vs 27 minutes [IQR: 21.5-34.6 minutes]; P < 0.001) than the 40-W group. There was no significant difference in freedom from all-atrial arrhythmias or procedural safety outcomes between 50-W and 40-W during HPSD ablation of paroxysmal AF. The use of 50-W was associated with a higher rate of first-pass PVI as well as shorter procedural times.
doi_str_mv 10.1016/j.jacep.2023.08.005
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2874258805</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2874258805</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-a55ff97aa08d718721dcb05e1aaddeaf2ba4dc19dd57c8ff4701c8a1728dc3b93</originalsourceid><addsrcrecordid>eNo1kNFKwzAYhYMgbsw9gSC59Kb1T9qsmXdlOidMHEzxsqRJumV0a03S6cCH2bPsyezYvDqHw8fhcBC6IRASIIP7VbgSUtchBRqFwEMAdoG6NAYWMCC8g_rOrQCAMMopia9QJ0o4xJTxLvplEHzircPxUR8bazYLPDGLZTCrvrXF82VlfdDmwptqg9O8PJmisof9TNjqZ-fWojzsU2-NKPHY5NaUJ-gBp_i1Kb2ReuPbrpmtXK2lN1uN575Ru2t0WYjS6f5Ze-hj_PQ-mgTTt-eXUToNakIHPhCMFcUwEQK4SghPKFEyB6aJEEppUdBcxEqSoVIskbwo4gSI5IIklCsZ5cOoh-5OvbWtvhrtfLY2Tup25kZXjcsoT45vcGAtentGm3ytVVZbsxZ2l_0_Fv0B4Qtwwg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2874258805</pqid></control><display><type>article</type><title>50-W vs 40-W During High-Power Short-Duration Ablation for Paroxysmal Atrial Fibrillation: A Multicenter Prospective Study</title><source>ScienceDirect®</source><creator>Costea, Alexandru ; Diaz, Juan Carlos ; Osorio, Jose ; Matos, Carlos D ; Hoyos, Carolina ; Goyal, Sandeep ; Te, Charles ; D'Souza, Benjamin ; Rastogi, Mohit ; Lopez-Cabanillas, Nestor ; Ibanez, Laura C ; Thorne, Christopher ; Varley, Allyson L ; Zei, Paul C ; Sauer, William H ; Romero, Jorge E</creator><creatorcontrib>Costea, Alexandru ; Diaz, Juan Carlos ; Osorio, Jose ; Matos, Carlos D ; Hoyos, Carolina ; Goyal, Sandeep ; Te, Charles ; D'Souza, Benjamin ; Rastogi, Mohit ; Lopez-Cabanillas, Nestor ; Ibanez, Laura C ; Thorne, Christopher ; Varley, Allyson L ; Zei, Paul C ; Sauer, William H ; Romero, Jorge E</creatorcontrib><description>High-power short-duration (HPSD) radiofrequency ablation of atrial fibrillation (AF) increases first-pass pulmonary vein isolation (PVI) and freedom from atrial arrhythmias while decreasing procedural time. However, the optimal power setting in terms of safety and efficacy has not been determined. This study compared the procedural characteristics and clinical outcomes of 50-W vs 40-W during HPSD ablation of paroxysmal AF. Patients from the REAL-AF prospective multicenter registry (Real-World Experience of Catheter Ablation for Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation) undergoing HPSD ablation of paroxysmal AF, either using 50-W or 40-W, were included. The primary efficacy outcome was freedom from all-atrial arrhythmias. The primary safety outcome was the occurrence of any procedural complication at 12 months. Secondary outcomes included procedural characteristics, AF-related symptoms, and the occurrence of transient ischemic attack or stroke at 12 months. A total of 383 patients were included. Freedom from all-atrial arrhythmias at 12 months was 80.7% in the 50-W group and 77.3% in the 40-W group (Log-rank P = 0.387). The primary safety outcome occurred in 3.7% of patients in the 50-W group vs 2.8% in the 40-W group (P = 0.646). The 50-W group had a higher rate of first-pass PVI (82.3% vs 76.2%; P = 0.040) as well as shorter procedural (67 minutes [IQR: 54-87.5 minutes] vs 93 minutes [IQR: 80.5-111 minutes]; P &lt; 0.001) and radiofrequency ablation times (15 minutes [IQR: 11.4-20 minutes] vs 27 minutes [IQR: 21.5-34.6 minutes]; P &lt; 0.001) than the 40-W group. There was no significant difference in freedom from all-atrial arrhythmias or procedural safety outcomes between 50-W and 40-W during HPSD ablation of paroxysmal AF. The use of 50-W was associated with a higher rate of first-pass PVI as well as shorter procedural times.</description><identifier>EISSN: 2405-5018</identifier><identifier>DOI: 10.1016/j.jacep.2023.08.005</identifier><identifier>PMID: 37804258</identifier><language>eng</language><publisher>United States</publisher><subject>Atrial Fibrillation ; Catheter Ablation - adverse effects ; Cryosurgery ; Humans ; Neoplasm Recurrence, Local - etiology ; Prospective Studies ; Time Factors</subject><ispartof>JACC. Clinical electrophysiology, 2023-12, Vol.9 (12), p.2573-2583</ispartof><rights>Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37804258$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Costea, Alexandru</creatorcontrib><creatorcontrib>Diaz, Juan Carlos</creatorcontrib><creatorcontrib>Osorio, Jose</creatorcontrib><creatorcontrib>Matos, Carlos D</creatorcontrib><creatorcontrib>Hoyos, Carolina</creatorcontrib><creatorcontrib>Goyal, Sandeep</creatorcontrib><creatorcontrib>Te, Charles</creatorcontrib><creatorcontrib>D'Souza, Benjamin</creatorcontrib><creatorcontrib>Rastogi, Mohit</creatorcontrib><creatorcontrib>Lopez-Cabanillas, Nestor</creatorcontrib><creatorcontrib>Ibanez, Laura C</creatorcontrib><creatorcontrib>Thorne, Christopher</creatorcontrib><creatorcontrib>Varley, Allyson L</creatorcontrib><creatorcontrib>Zei, Paul C</creatorcontrib><creatorcontrib>Sauer, William H</creatorcontrib><creatorcontrib>Romero, Jorge E</creatorcontrib><title>50-W vs 40-W During High-Power Short-Duration Ablation for Paroxysmal Atrial Fibrillation: A Multicenter Prospective Study</title><title>JACC. Clinical electrophysiology</title><addtitle>JACC Clin Electrophysiol</addtitle><description>High-power short-duration (HPSD) radiofrequency ablation of atrial fibrillation (AF) increases first-pass pulmonary vein isolation (PVI) and freedom from atrial arrhythmias while decreasing procedural time. However, the optimal power setting in terms of safety and efficacy has not been determined. This study compared the procedural characteristics and clinical outcomes of 50-W vs 40-W during HPSD ablation of paroxysmal AF. Patients from the REAL-AF prospective multicenter registry (Real-World Experience of Catheter Ablation for Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation) undergoing HPSD ablation of paroxysmal AF, either using 50-W or 40-W, were included. The primary efficacy outcome was freedom from all-atrial arrhythmias. The primary safety outcome was the occurrence of any procedural complication at 12 months. Secondary outcomes included procedural characteristics, AF-related symptoms, and the occurrence of transient ischemic attack or stroke at 12 months. A total of 383 patients were included. Freedom from all-atrial arrhythmias at 12 months was 80.7% in the 50-W group and 77.3% in the 40-W group (Log-rank P = 0.387). The primary safety outcome occurred in 3.7% of patients in the 50-W group vs 2.8% in the 40-W group (P = 0.646). The 50-W group had a higher rate of first-pass PVI (82.3% vs 76.2%; P = 0.040) as well as shorter procedural (67 minutes [IQR: 54-87.5 minutes] vs 93 minutes [IQR: 80.5-111 minutes]; P &lt; 0.001) and radiofrequency ablation times (15 minutes [IQR: 11.4-20 minutes] vs 27 minutes [IQR: 21.5-34.6 minutes]; P &lt; 0.001) than the 40-W group. There was no significant difference in freedom from all-atrial arrhythmias or procedural safety outcomes between 50-W and 40-W during HPSD ablation of paroxysmal AF. The use of 50-W was associated with a higher rate of first-pass PVI as well as shorter procedural times.</description><subject>Atrial Fibrillation</subject><subject>Catheter Ablation - adverse effects</subject><subject>Cryosurgery</subject><subject>Humans</subject><subject>Neoplasm Recurrence, Local - etiology</subject><subject>Prospective Studies</subject><subject>Time Factors</subject><issn>2405-5018</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNo1kNFKwzAYhYMgbsw9gSC59Kb1T9qsmXdlOidMHEzxsqRJumV0a03S6cCH2bPsyezYvDqHw8fhcBC6IRASIIP7VbgSUtchBRqFwEMAdoG6NAYWMCC8g_rOrQCAMMopia9QJ0o4xJTxLvplEHzircPxUR8bazYLPDGLZTCrvrXF82VlfdDmwptqg9O8PJmisof9TNjqZ-fWojzsU2-NKPHY5NaUJ-gBp_i1Kb2ReuPbrpmtXK2lN1uN575Ru2t0WYjS6f5Ze-hj_PQ-mgTTt-eXUToNakIHPhCMFcUwEQK4SghPKFEyB6aJEEppUdBcxEqSoVIskbwo4gSI5IIklCsZ5cOoh-5OvbWtvhrtfLY2Tup25kZXjcsoT45vcGAtentGm3ytVVZbsxZ2l_0_Fv0B4Qtwwg</recordid><startdate>202312</startdate><enddate>202312</enddate><creator>Costea, Alexandru</creator><creator>Diaz, Juan Carlos</creator><creator>Osorio, Jose</creator><creator>Matos, Carlos D</creator><creator>Hoyos, Carolina</creator><creator>Goyal, Sandeep</creator><creator>Te, Charles</creator><creator>D'Souza, Benjamin</creator><creator>Rastogi, Mohit</creator><creator>Lopez-Cabanillas, Nestor</creator><creator>Ibanez, Laura C</creator><creator>Thorne, Christopher</creator><creator>Varley, Allyson L</creator><creator>Zei, Paul C</creator><creator>Sauer, William H</creator><creator>Romero, Jorge E</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>202312</creationdate><title>50-W vs 40-W During High-Power Short-Duration Ablation for Paroxysmal Atrial Fibrillation: A Multicenter Prospective Study</title><author>Costea, Alexandru ; Diaz, Juan Carlos ; Osorio, Jose ; Matos, Carlos D ; Hoyos, Carolina ; Goyal, Sandeep ; Te, Charles ; D'Souza, Benjamin ; Rastogi, Mohit ; Lopez-Cabanillas, Nestor ; Ibanez, Laura C ; Thorne, Christopher ; Varley, Allyson L ; Zei, Paul C ; Sauer, William H ; Romero, Jorge E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-a55ff97aa08d718721dcb05e1aaddeaf2ba4dc19dd57c8ff4701c8a1728dc3b93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Atrial Fibrillation</topic><topic>Catheter Ablation - adverse effects</topic><topic>Cryosurgery</topic><topic>Humans</topic><topic>Neoplasm Recurrence, Local - etiology</topic><topic>Prospective Studies</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Costea, Alexandru</creatorcontrib><creatorcontrib>Diaz, Juan Carlos</creatorcontrib><creatorcontrib>Osorio, Jose</creatorcontrib><creatorcontrib>Matos, Carlos D</creatorcontrib><creatorcontrib>Hoyos, Carolina</creatorcontrib><creatorcontrib>Goyal, Sandeep</creatorcontrib><creatorcontrib>Te, Charles</creatorcontrib><creatorcontrib>D'Souza, Benjamin</creatorcontrib><creatorcontrib>Rastogi, Mohit</creatorcontrib><creatorcontrib>Lopez-Cabanillas, Nestor</creatorcontrib><creatorcontrib>Ibanez, Laura C</creatorcontrib><creatorcontrib>Thorne, Christopher</creatorcontrib><creatorcontrib>Varley, Allyson L</creatorcontrib><creatorcontrib>Zei, Paul C</creatorcontrib><creatorcontrib>Sauer, William H</creatorcontrib><creatorcontrib>Romero, Jorge E</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>JACC. Clinical electrophysiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Costea, Alexandru</au><au>Diaz, Juan Carlos</au><au>Osorio, Jose</au><au>Matos, Carlos D</au><au>Hoyos, Carolina</au><au>Goyal, Sandeep</au><au>Te, Charles</au><au>D'Souza, Benjamin</au><au>Rastogi, Mohit</au><au>Lopez-Cabanillas, Nestor</au><au>Ibanez, Laura C</au><au>Thorne, Christopher</au><au>Varley, Allyson L</au><au>Zei, Paul C</au><au>Sauer, William H</au><au>Romero, Jorge E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>50-W vs 40-W During High-Power Short-Duration Ablation for Paroxysmal Atrial Fibrillation: A Multicenter Prospective Study</atitle><jtitle>JACC. Clinical electrophysiology</jtitle><addtitle>JACC Clin Electrophysiol</addtitle><date>2023-12</date><risdate>2023</risdate><volume>9</volume><issue>12</issue><spage>2573</spage><epage>2583</epage><pages>2573-2583</pages><eissn>2405-5018</eissn><abstract>High-power short-duration (HPSD) radiofrequency ablation of atrial fibrillation (AF) increases first-pass pulmonary vein isolation (PVI) and freedom from atrial arrhythmias while decreasing procedural time. However, the optimal power setting in terms of safety and efficacy has not been determined. This study compared the procedural characteristics and clinical outcomes of 50-W vs 40-W during HPSD ablation of paroxysmal AF. Patients from the REAL-AF prospective multicenter registry (Real-World Experience of Catheter Ablation for Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation) undergoing HPSD ablation of paroxysmal AF, either using 50-W or 40-W, were included. The primary efficacy outcome was freedom from all-atrial arrhythmias. The primary safety outcome was the occurrence of any procedural complication at 12 months. Secondary outcomes included procedural characteristics, AF-related symptoms, and the occurrence of transient ischemic attack or stroke at 12 months. A total of 383 patients were included. Freedom from all-atrial arrhythmias at 12 months was 80.7% in the 50-W group and 77.3% in the 40-W group (Log-rank P = 0.387). The primary safety outcome occurred in 3.7% of patients in the 50-W group vs 2.8% in the 40-W group (P = 0.646). The 50-W group had a higher rate of first-pass PVI (82.3% vs 76.2%; P = 0.040) as well as shorter procedural (67 minutes [IQR: 54-87.5 minutes] vs 93 minutes [IQR: 80.5-111 minutes]; P &lt; 0.001) and radiofrequency ablation times (15 minutes [IQR: 11.4-20 minutes] vs 27 minutes [IQR: 21.5-34.6 minutes]; P &lt; 0.001) than the 40-W group. There was no significant difference in freedom from all-atrial arrhythmias or procedural safety outcomes between 50-W and 40-W during HPSD ablation of paroxysmal AF. The use of 50-W was associated with a higher rate of first-pass PVI as well as shorter procedural times.</abstract><cop>United States</cop><pmid>37804258</pmid><doi>10.1016/j.jacep.2023.08.005</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier EISSN: 2405-5018
ispartof JACC. Clinical electrophysiology, 2023-12, Vol.9 (12), p.2573-2583
issn 2405-5018
language eng
recordid cdi_proquest_miscellaneous_2874258805
source ScienceDirect®
subjects Atrial Fibrillation
Catheter Ablation - adverse effects
Cryosurgery
Humans
Neoplasm Recurrence, Local - etiology
Prospective Studies
Time Factors
title 50-W vs 40-W During High-Power Short-Duration Ablation for Paroxysmal Atrial Fibrillation: A Multicenter Prospective Study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T23%3A27%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=50-W%20vs%2040-W%20During%20High-Power%20Short-Duration%20Ablation%20for%C2%A0Paroxysmal%C2%A0Atrial%20Fibrillation:%20A%20Multicenter%20Prospective%20Study&rft.jtitle=JACC.%20Clinical%20electrophysiology&rft.au=Costea,%20Alexandru&rft.date=2023-12&rft.volume=9&rft.issue=12&rft.spage=2573&rft.epage=2583&rft.pages=2573-2583&rft.eissn=2405-5018&rft_id=info:doi/10.1016/j.jacep.2023.08.005&rft_dat=%3Cproquest_pubme%3E2874258805%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p126t-a55ff97aa08d718721dcb05e1aaddeaf2ba4dc19dd57c8ff4701c8a1728dc3b93%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2874258805&rft_id=info:pmid/37804258&rfr_iscdi=true